Brain Cholesterol Synthesis and Metabolism is Progressively Disturbed in the R6/1 Mouse Model of Huntington's Disease: A Targeted GC-MS/MS Sterol Analysis.
Level 5 - mechanism / opinion, no new human data
Preclinical animal model study
PubMed 26639223 · doi:10.3233/JHD-150170
What was done
The authors quantified cholesterol biosynthetic precursors, metabolites, and oxidation products in the striatum and cortex of R6/1 transgenic Huntington's disease mice and wild-type controls at 6, 12, 20, 24, and 28 weeks of age using GC-MS/MS. Motor phenotype progression was measured across 28 weeks using RotaRod testing and hind-paw clasping assays alongside weight monitoring.
What was found
Cholesterol synthesis precursors (lanosterol and lathosterol) were significantly reduced in both the striatum and cortex of R6/1 mice by 6 weeks of age, prior to motor dysfunction onset. Late in disease progression, 24(S)-hydroxycholesterol and 27-hydroxycholesterol altered significantly in the striatum specifically, and desmosterol levels increased at the final time point. Female R6/1 mice showed less severe weight loss and clasping phenotypes than males, but brain sterol concentrations showed no sex differences. The abstract does not report raw numerical values, effect sizes, or confidence intervals.
Why it matters
The findings show that brain cholesterol synthesis abnormalities precede motor symptom onset in this mouse model, highlighting early sterol pathways as potential therapeutic targets in Huntington's disease.
Limits
The study is limited to an animal model (R6/1 mice) and may not fully capture human pathology. The abstract omits sample sizes (n), absolute concentration values, and variance data, and does not evaluate therapeutic rescue.
Cited by
- contradicts In the central nervous system, cholesterol synthesis occurs exclusively through the desmosterol pathway, making circulating desmosterol a proxy for brain cholesterol synthesis, whereas lathosterol reflects peripheral cholesterol synthesis.